Browsing by Author "Rovira, Ana"

Sort by: Order: Results:

  • High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients
    Cañadas, Israel; Taus, Álvaro; González, Iria; Villanueva, Xavie; Gimeno, Javier; Pijuan, Lara; Dómine, Manuel; Sánchez-Font, Albert; Vollmer, Ivan; Menéndez, Silvia; Arpí, Oriol; Mojal, Sergi; Rojo, Federico; Rovira, Ana; Albanell, Joan; Arriola Aperribay, Edurne (Impact Journal, 2014)
    We have previously shown that Met activation through the hepatocyte growth factor (HGF) increases tumorogenesis, induces epithelial-to-mesenchymal transition (EMT) and chemoresistance in SCLC. We sought to evaluate circulating ...
  • MicroRNA-33b suppresses epithelial-mesenchymal transition repressing the MYC-EZH2 pathway in HER2+ breast carcinoma
    Pattanayak, Birlipta; Garrido Cano, Iris; Adam-Artigues, Anna; Tormo, Eduardo; Pineda, Begoña; Cabello, Paula; Alonso, Elisa; Bermejo, Begoña; Hernando, Cristina; Martínez, María Teresa; Rovira, Ana; Albanell Mestres, Joan; Rojo, Federico; Burgués, Octavio; Cejalvo, Juan M.; Lluch, Ana; Eroles, Pilar (Frontiers, 2020)
    Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) ...
  • miR-146a-5p Promotes angiogenesis and confers Trastuzumab Resistance in HER2+ breast cancer
    Cabello, Paula; Torres-Ruiz, Sandra; Adam-Artigues, Anna; Forés-Martos, Jaume; Martínez, María Teresa; Hernando, Cristina; Zazo, Sandra; Madoz-Gúrpide, Juan; Rovira, Ana; Burgués, Octavio; Rojo, Federico; Albanell Mestres, Joan; Lluch, Ana; Bermejo, Begoña; Cejalvo, Juan Miguel; Eroles, Pilar (MDPI, 2023)
    Trastuzumab treatment has significantly improved the prognosis of HER2-positive breast cancer patients. Despite this, resistance to therapy still remains the main clinical challenge. In order to evaluate the implication ...
  • mTOR inhibition and T-DM1 in HER2-positive breast cancer
    Casadevall Aguilar, David; Hernández Prat, Anna, 1984-; García-Alonso, Sara; Arpí Llucià, Oriol; Menéndez, Silvia; Qin, Mengjuan; Guardia Valenzuela, Cristina, 1990-; Morancho Armisen, Beatriz; Sánchez-Martín, Francisco Javier; Zazo, Sandra; Gavilán, Elena; Sabbaghi Mehrjardi, Mohammad Ali; Eroles, Pilar; Cejalvo, Juan M.; Lluch, Ana; Rojo, Federico; Pandiella, Atanasio; Rovira, Ana; Albanell Mestres, Joan (American Association for Cancer Research (AACR), 2022)
    In patients with trastuzumab-resistant HER2-positive breast cancer, the combination of everolimus (mTORC1 inhibitor) with trastuzumab failed to show a clinically significant benefit. However, the combination of mTOR ...
  • NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
    Santana-Hernández, Sara; Suárez Olmos, Jesús; Servitja Tormo, Sonia; Berenguer-Molins, Pau; Costa García, Marcel, 1989-; Comerma Blesa, Laura, 1983-; Rea, Anna; Perera Bel, Júlia; Menendez Romero, Silvia; Arpí Llucià, Oriol; Bermejo, Begoña; Martínez, María Teresa; Cejalvo, Juan Miguel; Comino-Méndez, Iñaki; Pascual, Javier; Alba, Emilio; López-Botet, M. (Miguel); Rojo, Federico; Rovira, Ana; Albanell Mestres, Joan; Muntasell i Castellví, Aura, 1972- (BioMed Central, 2024)
    Background: The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural ...
  • Role of SALL4 in HER2+ breast cancer progression: Regulating PI3K/AKT pathway
    Pattanayak, Birlipta; Lameirinhas, Ana; Torres-Ruiz, Sandra; Burgués, Octavio; Rovira, Ana; Martínez, María Teresa; Tapia, Marta; Zazo, Sandra; Albanell Mestres, Joan; Rojo, Federico; Bermejo, Begoña; Eroles, Pilar (MDPI, 2022)
    Treatment for the HER2+ breast cancer subtype is still unsatisfactory, despite breakthroughs in research. The discovery of various new molecular mechanisms of transcription factors may help to make treatment regimens more ...
  • The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
    Boll, Lilian Marie; Perera Bel, Júlia; Rodriguez-Vida, Alejo; Arpí Llucià, Oriol; Rovira, Ana; Juanpere, Nuria; Vázquez Montes de Oca, Sergio; Hernández Llodrà, Silvia; Lloreta, Josep, 1958-; Albà Soler, Mar; Bellmunt Molins, Joaquim, 1959- (Nature Research, 2023)
    Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment and can result in complete remissions even at advanced stages of the disease. However, only a small fraction of patients respond to the treatment. To ...
  • The novel oral mTORC1/2 inhibitor TAK-228 reverses trastuzumab resistance in HER2-positive breast cancer models
    Sanz Álvarez, Marta; Martín-Aparicio, Ester; Luque, Melani; Zazo, Sandra; Martínez-Useros, Javier; Eroles, Pilar; Rovira, Ana; Albanell Mestres, Joan; Madoz-Gúrpide, Juan; Rojo, Federico (MDPI, 2021)
    The use of anti-HER2 therapies has significantly improved clinical outcome in patients with HER2-positive breast cancer, yet a substantial proportion of patients acquire resistance after a period of treatment. The PI3K/AKT/mTOR ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking